

Oncology Today with Dr Neil Love: Key Presentations on Acute Myeloid Leukemia and Myelodysplastic Syndromes from ASH 2021

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following best describes outcomes from the Phase 3 PANTHER trial evaluating pevonedistat with azacitidine as front-line therapy for patients with higher-risk myelodysplastic syndromes (MDS)?**
 - Primary endpoint of event-free survival (EFS) was met
 - Primary/secondary endpoints of EFS/overall survival (OS) were met
 - Primary/secondary endpoints of EFS/OS were not met
- 2. Emerging data from clinical investigation of enasidenib monotherapy for patients with MDS and an IDH1 mutation revealed which of the following patient subgroups derived the highest overall response?**
 - Cohort A: High-risk MDS without response to azacitidine after 6 cycles
 - Cohort B: High-risk MDS without prior azacitidine/decitabine
 - Cohort C: Low-risk MDS with anemia post-erythropoiesis stimulating agent
 - All comers
- 3. Which of the following mutations is most commonly observed in patients with higher-risk MDS?**
 - TP53
 - IDH1
 - IDH2
 - DNMT3A
 - No mutation
- 4. Results from a pilot study evaluating CPX-351 for transplant-eligible patients with higher-risk MDS revealed a complete response of which value?**
 - 2%
 - 10%
 - 20%
 - 40%
- 5. Which of the following cohorts of patients with MDS harboring an IDH-1 mutation experienced the best overall responses to ivosidenib monotherapy in the Phase II IDIOME study?**
 - Cohort A: Higher-risk MDS without response to azacitidine after 6 cycles
 - Cohort B: Higher-risk MDS without prior azacitidine/decitabine
 - Cohort C: Lower-risk MDS with anemia post erythropoiesis-stimulating agent
 - All comers